Is there any reason that PAR couldn’t park the insanely expensive and time consuming task of gaining FDA approval and perhaps aim for approval in countries with less onerous approvals process and perhaps start to bring in revenue earlier….this revenue can then be put towards the formal FDA approvals and with the advantage of having several years of real life “paying” patient outcomes to include with the submission. There’s a big world outside of the US.
Sharewise Presentation 22/7/24, page-110
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |